Table 6 Process evaluation: study participant interviewee characteristics
Overall study participants (n = 152) (n, %) | Process evaluation interviewees (n = 31) (n, %) | |||
|---|---|---|---|---|
Trial arm (n, %) | ||||
SPI + TAU | 112 | 74% | 24 | 77% |
TAU only | 40 | 26% | 7 | 23% |
Age group | ||||
Age 18–25 | 43 | 28% | 11 | 35% |
Age 26–40 | 52 | 34% | 12 | 39% |
Age > 40 | 57 | 38% | 8 | 26% |
Gender | ||||
Female | 94 | 62% | 23 | 74% |
Male | 57 | 38% | 8 | 26% |
Non-binary | 1 | 1% | 0 | 0% |
History of self-harm with suicidal intent | ||||
0 or 1 | 42 | 28% | 11 | 35% |
2 or more | 110 | 72% | 20 | 65% |
Hospital recruitment site | ||||
H1 | 26 | 17% | 5 | 16% |
H2 | 59 | 39% | 10 | 32% |
H3 | 29 | 19% | 6 | 19% |
H4 | 38 | 25% | 10 | 32% |
Level of engagement (minimum dose received) | ||||
Intervention arm participants who reached minimum dose (SPI + 1 FU) | 91 | 81% | 23 | 96% |
Intervention arm participants who did not receive minimum dose | 21 | 19% | 1 | 4% |